Antithrombotic therapy for ischemic stroke requires tailoring to the individual patient and underlying stroke mechanism, balancing benefits against the increased risk of bleeding.
Stroke is a devastating condition with significant morbidity and mortality worldwide. Antithrombotic therapy plays a crucial role in both primary and secondary prevention of stroke events. Single or dual antiplatelet therapy is generally preferred in cases of large-artery atherosclerosis and small-vessel disease, whereas anticoagulation is recommended in conditions of blood stasis or hypercoagulable states that mostly result in red thrombi. However, the benefit of antithrombotic therapies must be weighed against the increased risk of bleeding, which can pose significant challenges in the pharmacological management of this condition. This review provides a comprehensive summary of the currently available evidence on antithrombotic therapy for ischemic stroke and outlines an updated therapeutic algorithm to support physicians in tailoring the strategy to the individual patient and the underlying mechanism of stroke.
Greco et al. (Sun,) conducted a review in Ischemic Stroke. Antithrombotic therapy was evaluated. Antithrombotic therapy for ischemic stroke requires tailoring to the individual patient and underlying stroke mechanism, balancing benefits against the increased risk of bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: